Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Milan - Delayed Quote EUR

Moderna, Inc. (1MRNA.MI)

Compare

32.03

+2.28

+(7.67%)

As of 11:37:07 AM GMT+1. Market Open.

Moderna, Alibaba & Tencent, BlackRock: Market Minute

Madison Mills examines the trending headlines Wall Street investors need to know on today's Market Minute. Moderna (MRNA) shares pop after a German court ruled that Pfizer (PFE) and BioNTech (BNTX) violated Moderna's COVID vaccine patent. Alibaba (BABA) and Tencent (TCEHY) shares are trading higher after Bernstein analysts boosted their price targets for the Chinese tech stocks. BlackRock (BLK) stock is in focus as the company takes the lead on the $22.8 billion deal to control two key Panama Canal ports. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Naomi Buchanan.

Yahoo Finance Video 17 hours ago

MRNA

TCEHY

TCTZF
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price surge on Hump Day. Earlier that day, a court in Düsseldorf, Germany ruled that a COVID patent held by Moderna had been violated by a pair of rivals, American pharmaceutical giant Pfizer and its partner, German biotech BioNTech. The two had collaborated on developing and bringing to market another go-to COVID jab during the pandemic, ultimately brand-named Comirnaty.

Motley Fool 11 hours ago

MRNA

^GSPC
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S. automakers.

Investopedia 13 hours ago

^GSPC

CRWD

MRNA
The Dow surges 500 points as Trump hands out some tariff relief

The Dow Jones Industrial Average rose by nearly 500 points, recovering from a steep decline earlier in the week as the major U.S. automakers are given a one-month exemption from new tariffs on Canadian and Mexican imports.

Quartz 13 hours ago

NVO

CRWD

MRNA
Equity Markets Rise as Trump Exempts Auto Makers From Tariffs

US benchmark equity indexes are on track to close higher on Wednesday after President Donald Trump e

PREMIUM
MT Newswires 13 hours ago

^GSPC

MRNA

COMP
Why Moderna (MRNA) Stock Is Rallying Today

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA’s Court Victory A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna’s mRNA patents. The court ordered BNTX and PFE […]

Insider Monkey 16 hours ago

MRNA

PFE

BNTX
Moderna Scores Legal Victory Over Pfizer, BioNTech in Patent Dispute

Moderna's Patent Power Play Forces Pfizer, BioNTech to Pay Up

GuruFocus.com 16 hours ago

PFE

MRNA

BNTX
Moderna Says Individualized Neoantigen Therapy on Track for 2027 Potential Approval

Moderna (MRNA) continues to expect potential approval of its investigational individualized neoantig

PREMIUM
MT Newswires 17 hours ago

MRNA
Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court

Pfizer (PFE) and its partner BioNTech (BNTX) have infringed a COVID-19 vaccine patent owned by Moder

PREMIUM
MT Newswires 18 hours ago

BNTX

PFE

MRNA
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent

DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation, though the ruling can still be appealed to a higher court. The court added that Pfizer and BioNTech had argued they were authorised by a press release from Moderna to use the technology behind the patent until the World Health Organization declared in May 2023 that COVID-19 was no longer a global health emergency.

Reuters 19 hours ago

PFE

MRNA

BNTX
Moderna Stock Is Surging. The CEO Bought $5 Million of Shares.

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October 2011.

Barrons.com 20 hours ago

MRNA
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%

Philippe Laffont, the founder of Coatue Management, has done just that, recently buying shares of a beaten-down growth stock that Wall Street predicts will surge 80% in the coming 12 months. Is Coatue's latest bet a potentially winning one that you should follow?

Motley Fool 2 days ago

MRNA
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

StockStory 2 days ago

SRPT

BMRN

ABBV
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they

PREMIUM
MT Newswires 2 days ago

MRNA

ABUS
Moderna receives MHRA marketing authorization for RSV vaccine

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older. The approval is based on data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults

TipRanks 4 days ago

MRNA
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

mRESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted ...

ACCESS Newswire 5 days ago

MRNA
Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock a sell?

Investor's Business Daily 5 days ago

MRNA
1 Healthcare Stock to Own for Decades and 2 to Ignore

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.3%. This drop is a stark contrast from the S&P 500’s 5.1% gain.

StockStory 5 days ago

AMN

MRNA

ELV
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Another industry also offers innovation and even game-changing products -- elements that could drive long-term returns for your portfolio. Companies in the space often focus on the research and development of cutting-edge technologies such as gene editing or messenger RNA to power the medicines of tomorrow. The "if" in the above sentence means, yes, there is risk involved in investing in biotech players, especially if they don't yet have products on the market.

Motley Fool 6 days ago

VKTX

MRNA

CRSP
Moderna Stock Slumps 7% On A Surprise Twist In The RFK Jr. Saga

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding.

Investor's Business Daily 6 days ago

MRNA

Performance Overview

Return	1MRNA.MI	S&P 500
YTD	-15.12%	-0.66%
1-Year	-64.03%	+14.45%
3-Year	-75.91%	+34.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna, Inc. (1MRNA.MI)

Moderna, Alibaba & Tencent, BlackRock: Market Minute

Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday

S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism

The Dow surges 500 points as Trump hands out some tariff relief

Equity Markets Rise as Trump Exempts Auto Makers From Tariffs

Why Moderna (MRNA) Stock Is Rallying Today

Moderna Scores Legal Victory Over Pfizer, BioNTech in Patent Dispute

Moderna Says Individualized Neoantigen Therapy on Track for 2027 Potential Approval

Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court

German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent

Moderna Stock Is Surging. The CEO Bought $5 Million of Shares.

Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

Moderna receives MHRA marketing authorization for RSV vaccine

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?

1 Healthcare Stock to Own for Decades and 2 to Ignore

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Moderna Stock Slumps 7% On A Surprise Twist In The RFK Jr. Saga

Performance Overview